Options mapped

Sickle cell disease: options by country

Sourced options by country plus visit-prep questions for Sickle cell disease. Each line links to its regulator, HTA, or guideline source. This page maps options; it does not recommend or rank them.

Options mappedRare diseaseLast checked June 2026

What this page does

Maps options by country

It maps sourced options by country alongside diagnosis wording, stage, test results, specialists, and trial-search terms.

What it does not do

Does not choose treatment

It does not rank treatments, recommend a choice, or decide clinical fit.

Where it comes from

Built on trusted sources

Every option links to a trusted regulator, HTA, or guideline source, and the list grows as new sources pass verification.

Information to gather before the next visit

Are recurrent VOCs/VOEs documented, and is autologous stem-cell transplant clinically appropriate?
What transplant-center, fertility, infection, and long-term follow-up issues apply?
Has voxelotor been stopped or avoided because of the withdrawal?
Is Casgevy being considered through NICE managed access, a trial, or another country pathway?

Trial-search terms to discuss

Sickle cell disease clinical trial

Options by country

Treatments by country

Regulatory and access status by country, from official sources. It shows what exists and where — not a recommendation.

United States

Exagamglogene autotemcel / Casgevy; lovotibeglogene autotemcel / Lyfgenia [1]FDA-approvedSCD diagnosis; gene therapy labels specify SCD and recurrent VOC/VOE history rather than a single genotype in FDA notice; Patients aged 12 years and older with recurrent VOCs for Casgevy; patients aged 12 years and older with history of VOEs for Lyfgenia; Oxbryta no longer recorded as current U.S. access. · Both gene therapies require stem-cell collection, myeloablative conditioning, infusion, and long-term follow-up. Lyfgenia has a hematologic malignancy boxed-warning caveat in the FDA notice. Oxbryta should not be represented as currently available. Confidence/conflicts: High for U.S. gene therapy approval and Oxbryta withdrawal status.
Exagamglogene autotemcel / Casgevy; lovotibeglogene autotemcel / Lyfgenia [1]FDA-approvedSCD diagnosis; gene therapy labels specify SCD and recurrent VOC/VOE history rather than a single genotype in FDA notice; Patients aged 12 years and older with recurrent VOCs for Casgevy; patients aged 12 years and older with history of VOEs for Lyfgenia; Oxbryta no longer recorded as current U.S. access. · Both gene therapies require stem-cell collection, myeloablative conditioning, infusion, and long-term follow-up. Lyfgenia has a hematologic malignancy boxed-warning caveat in the FDA notice. Oxbryta should not be represented as currently available. Confidence/conflicts: High for U.S. gene therapy approval and Oxbryta withdrawal status.
Exagamglogene autotemcel / Casgevy; lovotibeglogene autotemcel / Lyfgenia [1]FDA-approvedSCD diagnosis; gene therapy labels specify SCD and recurrent VOC/VOE history rather than a single genotype in FDA notice; Patients aged 12 years and older with recurrent VOCs for Casgevy; patients aged 12 years and older with history of VOEs for Lyfgenia; Oxbryta no longer recorded as current U.S. access. · Both gene therapies require stem-cell collection, myeloablative conditioning, infusion, and long-term follow-up. Lyfgenia has a hematologic malignancy boxed-warning caveat in the FDA notice. Oxbryta should not be represented as currently available. Confidence/conflicts: High for U.S. gene therapy approval and Oxbryta withdrawal status.
voxelotor / Oxbryta [2]Withdrawn worldwide (Sep 2024)SCD diagnosis; gene therapy labels specify SCD and recurrent VOC/VOE history rather than a single genotype in FDA notice; Patients aged 12 years and older with recurrent VOCs for Casgevy; patients aged 12 years and older with history of VOEs for Lyfgenia; Oxbryta no longer recorded as current U.S. access. · Voxelotor (Oxbryta) was voluntarily withdrawn from all worldwide markets in September 2024 for a safety signal (excess vaso-occlusive crises and deaths, including pediatric) and is NOT currently available or FDA-approved; it has not returned as of 2026. The FDA-approved/available options in this record are Casgevy and Lyfgenia ONLY.
voxelotor / Oxbryta [2]Withdrawn worldwide (Sep 2024)SCD diagnosis; gene therapy labels specify SCD and recurrent VOC/VOE history rather than a single genotype in FDA notice; Patients aged 12 years and older with recurrent VOCs for Casgevy; patients aged 12 years and older with history of VOEs for Lyfgenia; Oxbryta no longer recorded as current U.S. access. · Voxelotor (Oxbryta) was voluntarily withdrawn from all worldwide markets in September 2024 for a safety signal (excess vaso-occlusive crises and deaths, including pediatric) and is NOT currently available or FDA-approved; it has not returned as of 2026. The FDA-approved/available options in this record are Casgevy and Lyfgenia ONLY.
voxelotor / Oxbryta [2]Withdrawn worldwide (Sep 2024)SCD diagnosis; gene therapy labels specify SCD and recurrent VOC/VOE history rather than a single genotype in FDA notice; Patients aged 12 years and older with recurrent VOCs for Casgevy; patients aged 12 years and older with history of VOEs for Lyfgenia; Oxbryta no longer recorded as current U.S. access. · Voxelotor (Oxbryta) was voluntarily withdrawn from all worldwide markets in September 2024 for a safety signal (excess vaso-occlusive crises and deaths, including pediatric) and is NOT currently available or FDA-approved; it has not returned as of 2026. The FDA-approved/available options in this record are Casgevy and Lyfgenia ONLY.

European Union

Exagamglogene autotemcel / Casgevy [3]EMA authorisedSevere SCD; VOC history/managed-access criteria per NICE scope; voxelotor not a current EU option after suspension/withdrawal; Severe SCD aged 12 years and over for Casgevy in NICE managed-access context; Oxbryta safety suspension/withdrawal context for EU. · NICE managed access is not the same as permanent routine commissioning. EMA Oxbryta recommendation means new patients should not be started and alternatives should be discussed by clinicians. Confidence/conflicts: High for NICE managed-access and EMA Oxbryta suspension/withdrawal caveats. Casgevy holds an EU conditional marketing authorisation; the prior 'restricted' badge reflected the now-removed voxelotor entry.
Exagamglogene autotemcel / Casgevy [3]EMA authorisedSevere SCD; VOC history/managed-access criteria per NICE scope; voxelotor not a current EU option after suspension/withdrawal; Severe SCD aged 12 years and over for Casgevy in NICE managed-access context; Oxbryta safety suspension/withdrawal context for EU. · NICE managed access is not the same as permanent routine commissioning. EMA Oxbryta recommendation means new patients should not be started and alternatives should be discussed by clinicians. Confidence/conflicts: High for NICE managed-access and EMA Oxbryta suspension/withdrawal caveats. Casgevy holds an EU conditional marketing authorisation; the prior 'restricted' badge reflected the now-removed voxelotor entry.
voxelotor / Oxbryta [4]EMA authorisation suspended / withdrawnSevere SCD; VOC history/managed-access criteria per NICE scope; voxelotor not a current EU option after suspension/withdrawal; Severe SCD aged 12 years and over for Casgevy in NICE managed-access context; Oxbryta safety suspension/withdrawal context for EU. · Voxelotor (Oxbryta) is NOT a current option: Pfizer withdrew it worldwide on 25 Sep 2024; the EU marketing authorisation was suspended (European Commission decision made final 9 Dec 2025, following CHMP confirmation 17 Oct 2025) and it was withdrawn from the UK market 8 Oct 2024 — due to higher rates of death and vaso-occlusive crises. It should no longer be prescribed; patients previously on it should discuss alternatives with their clinician. Casgevy's genuine EU/UK authorisation status is unchanged.
voxelotor / Oxbryta [4]EMA authorisation suspended / withdrawnSevere SCD; VOC history/managed-access criteria per NICE scope; voxelotor not a current EU option after suspension/withdrawal; Severe SCD aged 12 years and over for Casgevy in NICE managed-access context; Oxbryta safety suspension/withdrawal context for EU. · Voxelotor (Oxbryta) is NOT a current option: Pfizer withdrew it worldwide on 25 Sep 2024; the EU marketing authorisation was suspended (European Commission decision made final 9 Dec 2025, following CHMP confirmation 17 Oct 2025) and it was withdrawn from the UK market 8 Oct 2024 — due to higher rates of death and vaso-occlusive crises. It should no longer be prescribed; patients previously on it should discuss alternatives with their clinician. Casgevy's genuine EU/UK authorisation status is unchanged.

Australia

acute vaso-occlusive-crisis supportive care; analgesia; hydration; oxygen where indicated; blood transfusion where indicated; chronic transfusion and/or hydroxyurea background context [5]Standard option (per Perth Children's Hospital / Child and Adolescent Health Service WA)sickle hemoglobin / HbS context; pediatric emergency department management of SCD pain/VOC and complications in Western Australia. · This is an emergency guideline from one Australian pediatric hospital and should not be generalized as a national formulary or adult-care pathway. It does not establish approval for any branded product. Confidence/conflicts: Medium-high for WA pediatric acute-care context; national and adult Australia pathways remain gaps.
hydroxyurea/hydroxycarbamide; pain management; regular blood transfusions; bone marrow or stem cell transplant where appropriate [6]Standard option (per Rare Awareness Rare Education Portal / Rare Voices Australia)inherited hemoglobin beta-globin / sickle hemoglobin context; Australian SCD management and supportive-care context. · The RARE Portal is educational and does not establish medication registration, PBS listing, transplant eligibility, or individual suitability. It advises discussion with the medical team. Confidence/conflicts: Medium-high for Australian supportive-management categories; product-specific Australian approvals remain separate gaps.
hydroxyurea/hydroxycarbamide; pain management; regular blood transfusions; bone marrow or stem cell transplant where appropriate [6]Standard option (per Rare Awareness Rare Education Portal / Rare Voices Australia)inherited hemoglobin beta-globin / sickle hemoglobin context; Australian SCD management and supportive-care context. · The RARE Portal is educational and does not establish medication registration, PBS listing, transplant eligibility, or individual suitability. It advises discussion with the medical team. Confidence/conflicts: Medium-high for Australian supportive-management categories; product-specific Australian approvals remain separate gaps.

Thailand

Deferasirox (Deferasirox Teva)[7]ApprovedSickle cell disease; chronic iron overload after transfusion support.; Chronic transfusional iron overload in other anemias, with sickle cell disease named in the clinical-evidence population; not a disease-modifying SCD therapy. · The indication is framed as chronic iron overload in other anemias, not an SCD-specific disease-modifying label. It does not establish hydroxyurea, gene therapy, transfusion-protocol, or acute VOC access in Thailand. Confidence/conflicts: Medium-high for Thailand label support for transfusional iron overload in other anemias and clinical evidence including SCD; not a direct SCD disease-modifying approval. No conflict recorded. Availability/reimbursement outside the approving regulator not established.

Canada

exagamglogene autotemcel (Casgevy)[8]EMA authorisedsevere SCD with recurrent vaso-occlusive crises; autologous CRISPR/Cas9-edited CD34+ cell therapy targeting BCL11A enhancer to increase fetal hemoglobin; Canadian SCD patients aged 12 years and older with recurrent VOCs; treatment-centre and HSCT-appropriateness requirements apply. · The monograph describes mobilization, apheresis, full myeloablative conditioning, rescue-cell backup, and treatment-centre requirements. It is not a simple outpatient medication and does not establish provincial access or individual eligibility. Confidence/conflicts: High for Canadian authorization and label logistics; payer implementation remains separately tracked. Availability/reimbursement outside the approving regulator not established.
exagamglogene autotemcel (Casgevy)[8]EMA authorisedsevere SCD with recurrent vaso-occlusive crises; autologous CRISPR/Cas9-edited CD34+ cell therapy targeting BCL11A enhancer to increase fetal hemoglobin; Canadian SCD patients aged 12 years and older with recurrent VOCs; treatment-centre and HSCT-appropriateness requirements apply. · The monograph describes mobilization, apheresis, full myeloablative conditioning, rescue-cell backup, and treatment-centre requirements. It is not a simple outpatient medication and does not establish provincial access or individual eligibility. Confidence/conflicts: High for Canadian authorization and label logistics; payer implementation remains separately tracked. Availability/reimbursement outside the approving regulator not established.
exagamglogene autotemcel (Casgevy)[9]CADTH reimbursement recommendationsevere SCD genotype and recurrent VOC history per reimbursement conditions; Canadian public-drug-plan reimbursement-with-conditions context for severe SCD with recurrent VOCs. · CDA-AMC reimbursement recommendations do not guarantee provincial/territorial implementation. The recommendation includes specialist prescribing, one-time treatment/no retreatment, and cost-reduction conditions. Confidence/conflicts: Medium-high for Canadian reimbursement recommendation; local implementation and center capacity remain gaps.
exagamglogene autotemcel (Casgevy)[9]CADTH reimbursement recommendationsevere SCD genotype and recurrent VOC history per reimbursement conditions; Canadian public-drug-plan reimbursement-with-conditions context for severe SCD with recurrent VOCs. · CDA-AMC reimbursement recommendations do not guarantee provincial/territorial implementation. The recommendation includes specialist prescribing, one-time treatment/no retreatment, and cost-reduction conditions. Confidence/conflicts: Medium-high for Canadian reimbursement recommendation; local implementation and center capacity remain gaps.
exagamglogene autotemcel (Casgevy)[9]CADTH reimbursement recommendationsevere SCD genotype and recurrent VOC history per reimbursement conditions; Canadian public-drug-plan reimbursement-with-conditions context for severe SCD with recurrent VOCs. · CDA-AMC reimbursement recommendations do not guarantee provincial/territorial implementation. The recommendation includes specialist prescribing, one-time treatment/no retreatment, and cost-reduction conditions. Confidence/conflicts: Medium-high for Canadian reimbursement recommendation; local implementation and center capacity remain gaps.
hydroxyurea/hydroxycarbamide; HLA-matched hematopoietic stem cell transplant (HSCT) background context [8]Health Canada approvedbeta-globin sickle hemoglobin context; Canadian severe SCD background-care context used in Health Canada's Casgevy review. · This is background context from a regulator review, not a product monograph for hydroxyurea in SCD and not a personalized transplant recommendation. It explicitly notes hydroxyurea is not specifically authorized in Canada for SCD. Confidence/conflicts: Medium-high for Canadian background-care context; hydroxyurea label/reimbursement details require separate source verification.
hydroxyurea/hydroxycarbamide; HLA-matched hematopoietic stem cell transplant (HSCT) background context [8]Health Canada approvedbeta-globin sickle hemoglobin context; Canadian severe SCD background-care context used in Health Canada's Casgevy review. · This is background context from a regulator review, not a product monograph for hydroxyurea in SCD and not a personalized transplant recommendation. It explicitly notes hydroxyurea is not specifically authorized in Canada for SCD. Confidence/conflicts: Medium-high for Canadian background-care context; hydroxyurea label/reimbursement details require separate source verification.

Sources

U.S. Food and Drug Administration — regulator approval notice · regulator approval notice
U.S. Food and Drug Administration — regulator approval notice · regulator approval notice
European Medicines Agency (EMA) — regulator safety/suspension notice · regulator safety/suspension notice
European Medicines Agency (EMA) — regulator safety/suspension notice · regulator safety/suspension notice
Perth Children's Hospital / Child and Adolescent Health Service WA — hospital emergency department guideline · hospital emergency department guideline
Rare Awareness Rare Education (RARE) Portal / Rare Voices Australia — Australian rare-disease educational portal · Australian rare-disease educational portal
Thai National Drug Information / Thai FDA-MOPH — SmPC PDF / regulator drug-information repository · SmPC PDF / regulator drug-information repository
Health Canada Drug and Health Product Portal — Summary Basis of Decision · Summary Basis of Decision
CDA-AMC / Canada's Drug Agency — reimbursement recommendation / health technology review · reimbursement recommendation / health technology review

This is official regulatory and access status only — not medical advice, not a recommendation, and not a statement about eligibility. Whether any option fits depends on your situation and your oncology team. Status changes over time; confirm the current position with the linked source. Last checked 2026-06-12.

Beyond approved care

In clinical trials & emerging options

Options that are not — or not yet — an approved standard where you live: studies, clinical trials, off-label use, and early evidence that your own oncologist may not raise. Each is labeled by how strong the evidence is. A listing here is information to research and discuss with your team; it does not mean a treatment is proven, safe for you, or available today.

In clinical trials

CTX001/exagamglogene autotemcel; BAH243 lentiviral vector gene therapy; CS-206; etavopivat; mitapivatClinical trial · NCT03745287Clinical trialTrial only (registry)China · Severe SCD genotype and recurrent VOC criteria for CTX001 trial; betaS/betaS, betaS/beta0 or betaS/beta+ genotype for China BAH243 and CS-206 trials; SCD diagnosis for etavopivat/mitapivat studies; Severe SCD with recurrent VOCs for CTX001; China gene-therapy studies after hydroxyurea failure or recurrent events per criteria excerpts; SCD with VOC and hemoglobin criteria for etavopivat/mitapivat. · Study statuses vary, including completed, recruiting, active-not-recruiting. Gene-therapy trial access requires transplant/gene-therapy center evaluation and conditioning requirements. Confidence/conflicts: High for registry cells; no country approval claim is made beyond FDA/NICE/EMA sources. ClinicalTrials.gov — clinical-trial registry
CTX001/exagamglogene autotemcel; BAH243 lentiviral vector gene therapy; CS-206; etavopivat; mitapivatClinical trial · NCT03745287Clinical trialTrial only (registry)China · Severe SCD genotype and recurrent VOC criteria for CTX001 trial; betaS/betaS, betaS/beta0 or betaS/beta+ genotype for China BAH243 and CS-206 trials; SCD diagnosis for etavopivat/mitapivat studies; Severe SCD with recurrent VOCs for CTX001; China gene-therapy studies after hydroxyurea failure or recurrent events per criteria excerpts; SCD with VOC and hemoglobin criteria for etavopivat/mitapivat. · Study statuses vary, including completed, recruiting, active-not-recruiting. Gene-therapy trial access requires transplant/gene-therapy center evaluation and conditioning requirements. Confidence/conflicts: High for registry cells; no country approval claim is made beyond FDA/NICE/EMA sources. ClinicalTrials.gov — clinical-trial registry
CTX001/exagamglogene autotemcel; BAH243 lentiviral vector gene therapy; CS-206; etavopivat; mitapivatClinical trial · NCT03745287Clinical trialTrial only (registry)China · Severe SCD genotype and recurrent VOC criteria for CTX001 trial; betaS/betaS, betaS/beta0 or betaS/beta+ genotype for China BAH243 and CS-206 trials; SCD diagnosis for etavopivat/mitapivat studies; Severe SCD with recurrent VOCs for CTX001; China gene-therapy studies after hydroxyurea failure or recurrent events per criteria excerpts; SCD with VOC and hemoglobin criteria for etavopivat/mitapivat. · Study statuses vary, including completed, recruiting, active-not-recruiting. Gene-therapy trial access requires transplant/gene-therapy center evaluation and conditioning requirements. Confidence/conflicts: High for registry cells; no country approval claim is made beyond FDA/NICE/EMA sources. ClinicalTrials.gov — clinical-trial registry
Deferasirox; inclacumab; placeboClinical trial · NCT00235391Clinical trialTrial only (registry)Thailand · SCD diagnosis; chronic transfusion iron overload context for deferasirox expanded-access record; Chronic iron overload from ongoing transfusions where locally approved chelators were inadequate in expanded-access record; post-index VOC re-admission reduction context for inclacumab. · Deferasirox expanded-access study is old/completed; inclacumab study is terminated. Current local chelation or anti-VOC treatment access requires fresh national source verification. Confidence/conflicts: Medium-high; registry cells verified, but current local approval/access remains source-pending. ClinicalTrials.gov — expanded-access / clinical-trial registry
Deferasirox; inclacumab; placeboClinical trial · NCT00235391Clinical trialTrial only (registry)Thailand · SCD diagnosis; chronic transfusion iron overload context for deferasirox expanded-access record; Chronic iron overload from ongoing transfusions where locally approved chelators were inadequate in expanded-access record; post-index VOC re-admission reduction context for inclacumab. · Deferasirox expanded-access study is old/completed; inclacumab study is terminated. Current local chelation or anti-VOC treatment access requires fresh national source verification. Confidence/conflicts: Medium-high; registry cells verified, but current local approval/access remains source-pending. ClinicalTrials.gov — expanded-access / clinical-trial registry
Deferasirox; inclacumab; placeboClinical trial · NCT00235391Clinical trialTrial only (registry)Thailand · SCD diagnosis; chronic transfusion iron overload context for deferasirox expanded-access record; Chronic iron overload from ongoing transfusions where locally approved chelators were inadequate in expanded-access record; post-index VOC re-admission reduction context for inclacumab. · Deferasirox expanded-access study is old/completed; inclacumab study is terminated. Current local chelation or anti-VOC treatment access requires fresh national source verification. Confidence/conflicts: Medium-high; registry cells verified, but current local approval/access remains source-pending. ClinicalTrials.gov — expanded-access / clinical-trial registry

A clinical-trial listing or early report shows an option is being studied — not that it works, that it is safe for any one person, or that a site is enrolling today. Whether any of these fits is a conversation for your oncology team and the trial team. Last checked 2026-06-12.